Business Context and Reporting Period
Company: BioXcel Therapeutics, Inc. (BTAI)
Filing Type: Form 8-K (Current Report)
Date of Report: November 21, 2024
Primary Event: Entry into a Fifth Amendment to Credit Agreement and Guaranty with lenders led by Oaktree Fund Administration LLC. The filing also details the appointment of a new independent director and updates regarding intellectual property.
Key Financial Metrics and Debt Structure
The filing focuses on debt restructuring rather than operational financial performance. Key terms of the amended Credit Agreement include:
- Interest Rate: Modified from a floating rate (Term SOFR + 7.50%) to a fixed rate of 13% per annum, effective retroactively to September 30, 2024.
- Interest Payment Terms: For quarterly periods ending Dec 31, 2024, Mar 31, 2025, and Jun 30, 2025, the Company may pay up to 10% of interest "in-kind" (PIK) by capitalizing it into the principal.
- Amortization: A one-time principal payment of $2.5 million is required by December 31, 2024. Quarterly amortization of 5.0% of funded loans begins March 31, 2026.
- Liquidity Covenants: Minimum cash liquidity reduced to $7.5 million (from $25.0 million) until March 30, 2025. It increases to $10.0 million on March 31, 2025, and $15.0 million on September 30, 2025.
- Equity Issuance: Lenders received new warrants to purchase 5.0 million shares at $0.01/share. Existing warrants (448,150 shares) were amended to lower the exercise price.
Note: The filing does not provide specific values for current revenue, net income, operating cash flow, or total debt outstanding as of the filing date.
Material Changes and Covenants
The Fifth Amendment introduces significant changes to the Company's financial obligations and operational constraints:
- Waivers Granted:
- Waiver of the "going concern" qualification requirement for the 2024 audit.
- Permanent waiver of the minimum revenue covenant.
- Waiver of the previous requirement to raise $50.0 million by November 30, 2024.
- New Capital Raising Covenants:
- Raise 1: At least $7.0 million in gross cash proceeds by November 27, 2024.
- Raise 2: At least $18.0 million in net cash proceeds by March 15, 2025 (commercially reasonable efforts by Feb 15, 2025).
- Raise 3: At least $29.0 million in net cash proceeds by August 15, 2025, or 30 days after the SERENITY At-Home Phase 3 trial data readout.
- Operational Restrictions:
- Cash expenditures must adhere to a board-approved budget, with disbursements capped at 115% of the bi-weekly budgeted amount.
- Prohibition on cash bonuses for employees/executives in fiscal years 2024 and 2025 without lender consent.
- Restrictions on increasing cash compensation for certain senior officers in 2025.
- Removal of flexibility to dispose of OnkosXcel assets or out-license its IP without consent.
Guidance, Outlook, and Governance
Management Commentary and Strategic Actions:
- Board Expansion: The Board size increased from six to seven. David Mack was appointed as an independent director, effective November 21, 2024. He joins the Compensation Committee and a newly formed Capital Raising Committee.
- Compensation for New Director: Mr. Mack receives $90,000 in cash (accelerated if removed after 4 months) and 325,077 RSUs vesting over 12 months.
- Strategic Review: The Company agreed to engage an investment banker to evaluate strategic options.
- Intellectual Property: U.S. Patent No. 12,138,247 (covering a method of treating agitation with oromucosal dexmedetomidine) was issued on November 12, 2024, and accepted for listing in the FDA Orange Book on November 18, 2024. Expiration is January 12, 2043.
Risks and Contingencies:
- The Company faces immediate liquidity pressure to meet the $7.0 million "Raise 1" deadline by November 27, 2024.
- Failure to meet future capital raising milestones could trigger default under the Credit Agreement.
- Increased interest costs due to the fixed 13% rate and potential PIK interest accumulation.
Investor Verification Checklist
- Confirm whether the Company successfully raised the required $7.0 million by the November 27, 2024 deadline.
- Review the Company's latest cash balance to assess compliance with the $7.5 million minimum liquidity covenant.
- Monitor the status of the SERENITY At-Home Phase 3 trial, as the final capital raise deadline is tied to its data readout.
- Verify the terms of the new warrants issued to lenders (5.0 million shares at $0.01) and the dilution impact on existing shareholders.
- Check for any subsequent filings regarding the appointment of the investment banker or progress on strategic options.